학술논문
Combining chemotherapy and checkpoint blockade in thoracic cancer: how to proceed?
Document Type
Report
Author
Source
Lung Cancer Management. December 2014, Vol. 3 Issue 6, p443, 15 p.
Subject
Language
English
ISSN
1758-1966
Abstract
Author(s): Wayne J Aston [sup.aff1] [sup.aff2] , Scott A Fisher [sup.aff1] [sup.aff2] , Andrea Khong [sup.aff1] [sup.aff2] , Clara Mok [sup.aff1] [sup.aff2] , Anna K Nowak [sup.aff1] [sup.aff2] [sup.aff3] , [...]
SUMMARY Given the impressive efficacy of immune checkpoint blockade in thoracic malignancies, and the recently discovered immune-stimulating properties of many cytotoxic drugs, a logical next step would be to combine these treatments. However, the rational design of clinical trials investigating these combinations is hampered by a lack of knowledge regarding the overall immunogenic effects of the different chemotherapeutics. Here, we give an overview of the field with regard to checkpoint blockade and the immunological effects of cytotoxic chemotherapeutics, with particular focus on preclinical and clinical studies investigating the combination of these two treatment modalities. We discuss the hurdles that need to be overcome in order to optimally exploit chemotherapy and immune checkpoint blockade combinations in thoracic cancers.
SUMMARY Given the impressive efficacy of immune checkpoint blockade in thoracic malignancies, and the recently discovered immune-stimulating properties of many cytotoxic drugs, a logical next step would be to combine these treatments. However, the rational design of clinical trials investigating these combinations is hampered by a lack of knowledge regarding the overall immunogenic effects of the different chemotherapeutics. Here, we give an overview of the field with regard to checkpoint blockade and the immunological effects of cytotoxic chemotherapeutics, with particular focus on preclinical and clinical studies investigating the combination of these two treatment modalities. We discuss the hurdles that need to be overcome in order to optimally exploit chemotherapy and immune checkpoint blockade combinations in thoracic cancers.